



## Jazz Pharmaceuticals Announces Participation In Three Investor Conferences In November

November 10, 2012

DUBLIN, Nov. 9, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that the company will participate in three upcoming investor conferences. A live webcast of each presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at [www.jazzpharmaceuticals.com](http://www.jazzpharmaceuticals.com). The conferences and presentation times include:

- Lazard Capital Markets 9<sup>th</sup> Annual Healthcare Conference in New York, NY on Wednesday, November 14, 2012 at 8:00 a.m. EST/1:00 p.m. GMT. Bruce Cozadd, chairman and chief executive officer, will provide a business update;
- Credit Suisse 2012 Healthcare Conference in Phoenix, AZ on Thursday, November 15, 2012 at 8:30 a.m. MST/10:30 a.m. EST/3:30 p.m. GMT. Bruce Cozadd will provide a business update;
- Piper Jaffray 24th Annual Healthcare Conference in New York, NY on Wednesday, November 28, 2012 at 10:00 a.m. EST/3:00 p.m. GMT. Kate Falberg, executive vice president and chief financial officer, will provide a business update.

An archived version of each webcast will be available for at least one week following each respective presentation on the Investors section of the company's website at [www.jazzpharmaceuticals.com](http://www.jazzpharmaceuticals.com).

### **About Jazz Pharmaceuticals**

Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem<sup>®</sup> (sodium oxybate) oral solution, Erwinaze<sup>®</sup> (asparaginase *Erwinia chrysanthemi*), Prialt<sup>®</sup> (ziconotide) intrathecal infusion, Luvox CR<sup>®</sup> (fluvoxamine maleate), FazaClo<sup>®</sup> (clozapine, USP) HD and FazaClo LD. Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by its international division, EUSA Pharma.

SOURCE Jazz Pharmaceuticals plc

William Craumer, Director, Investor Relations, Jazz Pharmaceuticals, Ireland + 353 1 634 3211, U.S. +-1-650-496-2750